Last reviewed: May 15, 2026
Last updated: May 15, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Shed Cost has emerged as a telehealth platform positioning itself as a transparent, cost-focused alternative for GLP-1 medication access. The platform emphasizes simplified pricing models for semaglutide and tirzepatide, addressing patient concerns about the steep out-of-pocket costs associated with branded medications.
Why this matters: Shed Cost appeals to patients seeking affordability and straightforward treatment pathways. However, emerging research suggests individual genetic variations in peptide signaling pathways may influence both medication efficacy and optimal dosing—factors that generic cost models alone may not capture. PlexusDx takes a precision-wellness approach, combining compounded medications from licensed 503A pharmacies with optional genetic insights to support more informed clinical conversations.
Shed Cost's Market Position and Pricing Model
Shed Cost differentiates itself through transparent, flat-rate pricing for GLP-1 medications and streamlined telehealth consultations. The platform targets budget-conscious patients, offering semaglutide and tirzepatide at lower price points than traditional branded pharmaceuticals like Ozempic, Wegovy, or Mounjaro.
Shed Cost operates via remote provider consultations and direct medication shipping, reducing overhead associated with in-office visits. This model appeals to patients in rural or underserved areas. However, the platform does not currently integrate genetic assessment tools to identify individual predispositions that may affect treatment response or optimal dosing strategies.
Cost vs. Outcomes Framework: Beyond Price Tags
While Shed Cost emphasizes affordability, research increasingly shows that lowest-cost treatment is not always highest-value treatment. Genetic factors in the GLP1R, GIPR, FTO, and MC4R genes influence baseline metabolic rate, appetite signaling, and medication responsiveness. A patient with specific genetic variants may achieve better outcomes on tirzepatide than semaglutide—or vice versa—independent of cost.
| Treatment Factor |
Shed Cost Model |
Precision-Informed Approach |
| Pricing Transparency |
Flat-rate, simplified fees |
Tiered pricing; genetic test adds $99–$298 |
| Genetic Assessment |
Not included |
Optional Precision Peptide Genetic Test reveals peptide pathway predispositions |
| Medication Options |
Semaglutide, tirzepatide |
Compounded semaglutide, tirzepatide, GLP-Squared dual compound, microdose protocol |
| Provider Consultation |
Telehealth only |
Telehealth with genetic context available for discussion |
Genetic Predispositions: A Missing Layer in Shed Cost's Model
Shed Cost's cost-first approach does not currently address genetic predispositions in peptide signaling. Variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) may help providers understand baseline metabolic risk and predicted medication responsiveness.
PlexusDx's Precision Peptide Genetic Test can support a more personalized conversation with your healthcare provider. The test reveals predispositions in these key peptide genetic pathways, allowing providers to contextualize treatment selection and dosing within your individual biology—not just your budget.
Safety, Eligibility, and Realistic Expectations
Shed Cost's remote model requires thorough medical screening. Patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, uncontrolled diabetes, or severe renal impairment should not use GLP-1 medications. Shed Cost's providers should address these contraindications during intake.
Neither Shed Cost nor any telehealth platform can guarantee specific weight loss outcomes or predict exact medication response. Realistic expectations: average 5–15% body weight reduction with GLP-1 monotherapy, higher with compounded dual-peptide protocols or combined lifestyle changes. Work with your provider to set individualized targets based on your health status and goals.
How PlexusDx Supports a More Personalized Approach
Genetic predispositions in peptide pathways—such as variants in GLP1R and GIPR genes—may help provide context for why some patients respond robustly to semaglutide while others see modest benefit. Shed Cost does not assess these factors, but personalized approaches do account for them.
PlexusDx's Precision Peptide Genetic Test ($99 add-on or $298 standalone) identifies predispositions that can support a more informed conversation with your qualified healthcare provider. This test does not predict exact medication response, but it may reveal relevant information about your individual peptide signaling biology.
If you choose PlexusDx, our compounded semaglutide ($149/mo), tirzepatide ($249/mo), and dual-compound GLP-Squared ($249/mo) from licensed 503A pharmacies offer cost-effective alternatives to branded medications. Combined with optional genetic insight, this approach supports precision wellness conversations with your provider.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What exactly is Shed Cost, and how is it different from other telehealth GLP-1 platforms?
Shed Cost is a telehealth platform focused on transparent, simplified pricing for GLP-1 medications like semaglutide and tirzepatide. It emphasizes affordability and remote consultations but does not currently integrate genetic predisposition testing into its treatment model.
Does Shed Cost offer genetic testing or personalization?
No. Shed Cost's model is cost- and convenience-focused, without genetic assessment. PlexusDx offers optional Precision Peptide Genetic Testing to contextualize peptide pathway predispositions with your provider.
How do PlexusDx compounded medications compare to Shed Cost's offerings in price and outcomes?
PlexusDx compounded semaglutide and tirzepatide range $149/mo from licensed 503A pharmacies. Shed Cost emphasizes flat pricing; PlexusDx offers tiered options with optional genetic insight to support precision dosing conversations with your provider.
Is Shed Cost safe, and what patients should avoid GLP-1 treatment altogether?
GLP-1 therapy is contraindicated in patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, uncontrolled diabetes, or severe renal impairment. Shed Cost's providers should conduct thorough medical screening during intake.
Can genetic testing predict whether I'll respond well to GLP-1 medication?
The Precision Peptide Genetic Test reveals predispositions in peptide signaling pathways (GLP1R, GIPR, FTO, MC4R) that may provide context—but does not predict exact response. A qualified provider should interpret results within your full clinical picture.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Shed Price: GLP-1 Compounding Cost Strategy & Precision Alternatives
Orderly Meds Reviews: Evaluating Compounded GLP-1 Pharmacy Safety Standards